Portola Pharmaceuticals Alternatives & Competitors
12 companies similar to Portola Pharmaceuticals
Sarepta Therapeutics
Dragging Tomorrow Into Today.
Cambridge, United States
Prevail Therapeutics
Wholly owned subsidiary of Eli Lilly and Company
New York, United States
Affinia Therapeutics
Building the next generation of gene therapies
Waltham, United States
Alexion Pharmaceuticals, Inc.
Transforming Lives, Every Day.
Boston, United States
Track all Portola Pharmaceuticals competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Lumos Pharma
Transforming Lives with Rare Focus
Austin, United States
Neumora
Pioneering a new era of medicines for brain diseases
Watertown, United States
Alltrna
The world’s first transfer RNA (tRNA) platform company. We are unlocking the vast therapeu...
Cambridge, United States
Avalyn Pharma
Revolutionizing respiratory care with every breath
Boston, United States
Taysha Gene Therapies
Taysha Gene Therapies is focused on advancing AAV-based gene therapies for severe monogeni...
Dallas, United States
Nuvamid
A clinical stage biotech focused on the research and use of nucleotides, as therapeutics f...
Nyon, Switzerland
Jazz Pharmaceuticals
Identifying, developing and commercializing meaningful products that address unmet medical...
Dublin, Ireland
Adamant Health
Revolutionizing the care of Parkinson’s disease.
Kuopio, Finland
About Portola Pharmaceuticals
Research and Development in Rare Diseases, Clinical Trials Design and Execution, Patient-Centric Support Programs, Diagnostics Innovation, Business Development Partnerships, Discovery Partnerships
Patients with Rare Diseases, Healthcare Providers in Rare Disease, Biopharmaceutical Partners, Regulatory Agencies, Medical Community Focused on Rare Disorders
Biopharmaceutical, Cardiovascular Diseases, Autoimmune Diseases, Thrombosis, Hematologic Disorders, Factor Xa Inhibitor, Acute Coronary Syndrome, Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Myocardial Infarction, Stroke Prevention, SYK/JAK Inhibitor, Oncology, Chronic Inflammatory Diseases
B2B, D2C, B2D
Product Sales, Licensing
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Portola Pharmaceuticals and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Portola Pharmaceuticals on 12 Mar 2026. The 12 companies listed here were last checked between 13 Nov 2025 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.